MRKCL Stock Overview
Operates as a healthcare company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Merck & Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$99,470.00 |
| 52 Week High | US$130,550.00 |
| 52 Week Low | US$91,770.00 |
| Beta | 0.40 |
| 1 Month Change | 0% |
| 3 Month Change | -6.34% |
| 1 Year Change | 8.34% |
| 3 Year Change | 50.22% |
| 5 Year Change | n/a |
| Change since IPO | 67.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRKCL | CL Pharmaceuticals | CL Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 8.3% | 0% | 0% |
Return vs Industry: MRKCL exceeded the CL Pharmaceuticals industry which returned -25.4% over the past year.
Return vs Market: MRKCL underperformed the CL Market which returned 10.6% over the past year.
Price Volatility
| MRKCL volatility | |
|---|---|
| MRKCL Average Weekly Movement | 1.8% |
| Pharmaceuticals Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in CL Market | 0% |
| 10% least volatile stocks in CL Market | 0% |
Stable Share Price: MRKCL has not had significant price volatility in the past 3 months compared to the CL market.
Volatility Over Time: MRKCL's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1891 | 71,000 | Rob Davis | www.merck.com |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Merck & Co., Inc. Fundamentals Summary
| MRKCL fundamental statistics | |
|---|---|
| Market cap | CL$249.85t |
| Earnings (TTM) | CL$11.99t |
| Revenue (TTM) | CL$62.36t |
20.8x
P/E Ratio4.0x
P/S RatioIs MRKCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRKCL income statement (TTM) | |
|---|---|
| Revenue | US$63.17b |
| Cost of Revenue | US$14.79b |
| Gross Profit | US$48.39b |
| Other Expenses | US$36.24b |
| Earnings | US$12.15b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 04, 2025
| Earnings per share (EPS) | 4.80 |
| Gross Margin | 76.59% |
| Net Profit Margin | 19.23% |
| Debt/Equity Ratio | 85.6% |
How did MRKCL perform over the long term?
See historical performance and comparisonDividends
3.2%
Current Dividend Yield63%
Payout RatioDoes MRKCL pay a reliable dividends?
See MRKCL dividend history and benchmarks| Merck dividend dates | |
|---|---|
| Ex Dividend Date | Dec 16 2024 |
| Dividend Pay Date | Jan 08 2025 |
| Days until Ex dividend | 2 days |
| Days until Dividend pay date | 21 days |
Does MRKCL pay a reliable dividends?
See MRKCL dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/17 02:31 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Merck & Co., Inc. is covered by 61 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Fabrizio Spagna | Axia Financial Research |
| Ishan Majumdar | Baptista Research |